Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neurofibromatoses × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 28 Carcinoma, Hepatocellular 15 Prostatic Neoplasms 11 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Brain Neoplasms 6 Sarcoma 5 Neuroendocrine Tumors 5 Urinary Bladder Neoplasms 4 Melanoma 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Breast Neoplasms 4 Recurrence 3 Pancreatic Neoplasms 3 Osteosarcoma 3 Lung Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Thyroid Diseases 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Glioma 2 Glioblastoma 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Neuroendocrine 2

Interventions

mirdametinib 2 tipifarnib 1 pirfenidone 1 emvododstat 1 cabozantinib 1 binimetinib 1 Sunitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡